Clinical Trial Update: Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Cytotect CP, a hyperimmune anti-CMV IVIg, as prophylaxis against cytomegalovirus infection in patients with acute grade II-IV GVHD afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Cytotect CP (Hyperimmune anti-CMV IVIg)

Snippet

Sponsor: University Hospital, Lille | Conditions: Cytomegalovirus Infections | Phase 2 | Status: TERMINATED